Synergistic Inulin-Sulfonylurea Composition for Diabetes

The patent applies parameter changes by specifically defining the degree of polymerization (DP) range of inulin to be between 2-25 (preferably 3-10, most preferably 3-5). This parameter specification transforms the heterogeneous inulin preparations into a standardized form that ensures consistent and predictable blood glucose control when combined with sulfonylureas, while maintaining the ability to use various natural inulin sources.

The patent applies composite materials by creating a synergistic combination of inulin (with specifically defined DP 2-25) and sulfonylureas. This composite approach allows achieving better blood glucose control at lower sulfonylurea doses because the inulin component enhances the overall efficacy. The synergy between the two components means that the combination is more effective than the sum of individual effects, thereby reducing the required sulfonylurea dosage and minimizing associated side effects.

The patent specifies the DP parameter of inulin to be between 2-25 (preferably 3-10, most preferably 3-5), which provides a clear manufacturing target while maintaining reasonable formulation simplicity. This parameter definition strikes a balance between ease of manufacture and therapeutic predictability, as it does not require complete purification to a single DP value but rather control within a specific range that ensures consistent therapeutic outcomes.